Nuvation Bio Statistics
Total Valuation
Nuvation Bio has a market cap or net worth of $796.22 million. The enterprise value is $246.26 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvation Bio has 340.26 million shares outstanding. The number of shares has increased by 43.14% in one year.
| Current Share Class | 339.26M |
| Shares Outstanding | 340.26M |
| Shares Change (YoY) | +43.14% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 25.06% |
| Owned by Institutions (%) | 55.50% |
| Float | 229.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.60 |
| Forward PS | 26.92 |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.15 |
| EV / EBITDA | 1.22 |
| EV / EBIT | 1.23 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.39, with a Debt / Equity ratio of 0.15.
| Current Ratio | 9.39 |
| Quick Ratio | 9.26 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.28 |
| Debt / FCF | n/a |
| Interest Coverage | 293.03 |
Financial Efficiency
Return on equity (ROE) is -44.84% and return on invested capital (ROIC) is 25.63%.
| Return on Equity (ROE) | -44.84% |
| Return on Assets (ROA) | 20.17% |
| Return on Invested Capital (ROIC) | 25.63% |
| Return on Capital Employed (ROCE) | 34.51% |
| Revenue Per Employee | $65,250 |
| Profits Per Employee | -$922,264 |
| Employee Count | 220 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.48% in the last 52 weeks. The beta is 1.35, so Nuvation Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | -21.48% |
| 50-Day Moving Average | 2.21 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 52.33 |
| Average Volume (20 Days) | 4,172,647 |
Short Selling Information
The latest short interest is 71.29 million, so 20.95% of the outstanding shares have been sold short.
| Short Interest | 71.29M |
| Short Previous Month | 56.08M |
| Short % of Shares Out | 20.95% |
| Short % of Float | 31.13% |
| Short Ratio (days to cover) | 9.32 |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $14.36 million and -$202.90 million in losses. Loss per share was -$0.63.
| Revenue | 14.36M |
| Gross Profit | 3.95M |
| Operating Income | 200.43M |
| Pretax Income | -510.72M |
| Net Income | -202.90M |
| EBITDA | 201.48M |
| EBIT | 200.43M |
| Loss Per Share | -$0.63 |
Full Income StatementBalance Sheet
The company has $607.72 million in cash and $57.76 million in debt, giving a net cash position of $549.96 million or $1.62 per share.
| Cash & Cash Equivalents | 607.72M |
| Total Debt | 57.76M |
| Net Cash | 549.96M |
| Net Cash Per Share | $1.62 |
| Equity (Book Value) | 372.91M |
| Book Value Per Share | 1.09 |
| Working Capital | 556.85M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$168.19 million and capital expenditures -$388,000, giving a free cash flow of -$168.58 million.
| Operating Cash Flow | -168.19M |
| Capital Expenditures | -388,000 |
| Free Cash Flow | -168.58M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | 27.54% |
| Operating Margin | 1,396.27% |
| Pretax Margin | -1,413.43% |
| Profit Margin | n/a |
| EBITDA Margin | 1,403.56% |
| EBIT Margin | 1,396.27% |
| FCF Margin | n/a |
Dividends & Yields
Nuvation Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.14% |
| Shareholder Yield | -43.14% |
| Earnings Yield | -25.48% |
| FCF Yield | -21.17% |
Analyst Forecast
The average price target for Nuvation Bio is $7.83, which is 234.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.83 |
| Price Target Difference | 234.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
